An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)

The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01276405

Enrollment

123

Registered

2011-01-13

Start date

2010-03-31

Completion date

2015-10-31

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, over the age of 18 years * Presence of colon adenocarcinoma * Surgical resection for colon cancer stage III (Duke C) * Prior adjuvant therapy with Xeloda monotherapy

Exclusion criteria

* Contraindications for Xeloda

Design outcomes

Primary

Measure	Time frame
Disease-free survival	3 years

Secondary

Measure	Time frame
Safety (Incidence of adverse events)	3 years

Countries

Romania

Outcome results